Information and calculation tools by Rachid Asen. Not investment advice or research.

Disclaimer. Information tool. Compiles data published by NSE and BSE and calculations from the exchanges' published ESM and ASM criteria. Prices are end-of-day, not live: updated each evening after trading ends. Ethical business criteria are matched by AI, which can make mistakes; this is a criteria match, not a certification, fatwa, rating or advice. Check the company's filings. Not investment advice, research or a recommendation to buy, sell or hold any security; not SEBI-registered as an Investment Adviser or Research Analyst. Calculated dates are the earliest a security could become eligible; inclusion, stage changes and exit are decided solely by the exchanges. ESM, ASM and GSM shortlisting are surveillance measures and not an adverse action against the company. Data may be delayed or inaccurate; verify with the exchange.

SurveillanceLabby Rachid AsenSign in
Market closedPro tools are for Pro members only. Pro access requires signing an NDA.Pro needs an NDA.Request Pro accessRequest accessIST

Gufic Biosciences Limited

GUFICBIO (NSE) · GUFICBIO (BSE 509079) · ISIN INE742B01025 · Pharmaceuticals · Est. 1984 · listed 2004 · website

Not on any surveillance list

In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹260.82 cr and profit after tax ₹22.46 cr. Revenue was 14.9% higher than in Q1 FY26.

Open the full company file Every section, filings and your notes, in the app.

Quarterly results

Quarterly results, ₹ crore (as filed)
QuarterRevenueProfit after taxEPS (₹)Filed
Q1 FY27 standalone₹260.82 cr₹22.46 cr2.2414 Aug 2026
Q4 FY26 standalone₹252.05 cr₹20.57 cr2.0529 May 2026
Q3 FY26 standalone₹231.09 cr₹15.56 cr1.5513 Feb 2026
Q2 FY26 standalone₹230.42 cr₹14.94 cr1.4914 Nov 2025
Q1 FY26 standalone₹226.91 cr₹12.07 cr1.2013 Aug 2025
Q4 FY25 standalone₹205.02 cr₹7.97 cr0.8030 May 2025
Q3 FY25 standalone₹614.79 cr₹61.96 cr6.1814 Feb 2025
Q2 FY25 standalone₹406.99 cr₹42.63 cr4.2515 Nov 2024

Balance sheet

Balance sheet, ₹ crore (as filed)
As ofTotal equityBorrowingsTotal assets
31 Mar 2026 standalone₹664.18 cr₹385.16 cr₹1,341.59 cr
30 Sep 2025 standalone₹628.55 cr₹346.43 cr₹1,268.45 cr
31 Mar 2025 standalone₹601.36 cr₹310.37 cr₹1,169.63 cr

Shareholding

Shareholding pattern, Sep 2026
PromoterFIIDIIPublic
72.50%0.45%3.38%27.50%

Other companies in Pharmaceuticals

Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.

Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.